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Introduction {#apt13882-sec-0006}
============

Chronic infection with hepatitis C virus (HCV) causes significant morbidity, mortality and costs in the USA.[1](#apt13882-bib-0001){ref-type="ref"} There is a wide variation in the genotype distribution of HCV infection by countries. In the USA, genotype 1 (GT1) predominates (75.3%), with subtype 1a (GT1a) being the most prevalent subtype.[2](#apt13882-bib-0002){ref-type="ref"} There has been also a temporal shift towards more predominance of genotype 1a compared with genotype 1b in the USA.

Estimates of prevalence of NS5A resistance‐associated variants (RAVs) vary by study, the method of detection, and the cuff value for determining resistance. In phase 2 or 3 programme, RAVs prevalence among GT1a patients from the USA, defined as any change from reference identified by population sequencing at NS5A amino acid positions 28, 30, 31 or 93, was estimated at 12% for elbasvir/grazoprevir (EBR/GZR).[3](#apt13882-bib-0003){ref-type="ref"}, [4](#apt13882-bib-0004){ref-type="ref"} RAVs prevalence identified by population sequencing at positions 24, 28, 30, 31 or 93 was 13% in the ledipasvir/sofosbuvir (LDV/SOF) with ribavirin (RBV) clinical trial studies.[5](#apt13882-bib-0005){ref-type="ref"}, [6](#apt13882-bib-0006){ref-type="ref"}

Baseline presence of NS5A RAVs can attenuate the efficacy of new direct‐acting antivirals.[6](#apt13882-bib-0006){ref-type="ref"}, [7](#apt13882-bib-0007){ref-type="ref"}, [8](#apt13882-bib-0008){ref-type="ref"} For example, when assessing the relevance of baseline NS5A RAVs from samples of treatment‐naive patients or prior relapsers with HCV genotype 1a using a population sequencing assay, Jacobson *et al*.[9](#apt13882-bib-0009){ref-type="ref"} found that baseline NS5A RAVs reduced the efficacy of the EBR/GZR regimen (12 weeks, no RBV) from 98% (345/352) to 86% (74/86). There was no impact of baseline NS5A RAVs on efficacy among patients who received EBR/GZR+RBV (16 weeks, with RBV).[9](#apt13882-bib-0009){ref-type="ref"}

Testing for RAVs among some patients (e.g. with cirrhosis) is recommended by the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) prior to selecting the next HCV treatment regimen.[10](#apt13882-bib-0010){ref-type="ref"} Once the RAVs status of the patients has been determined, it is not clear what should be the optimal treatment regimen for patients with a given RAVs status.[11](#apt13882-bib-0011){ref-type="ref"}

By increasing the expected sustained virological response (SVR) rates, the use of testing has the potential of influencing the course of the disease, thereby further reducing the incidence of liver‐related complications, deaths and associated disease management costs. However, testing all GT1a patients at baseline introduces additional costs, and whether regimens based on RAVs testing provide sufficient value remains to be determined. The main objective of our study was to assess the cost‐effectiveness of baseline testing for NS5A RAVs in EBR/GZR‐treated patients compared without testing and with current treatments for GT1a patients in the USA.

Materials and methods {#apt13882-sec-0007}
=====================

Model overview and assumptions {#apt13882-sec-0008}
------------------------------

We developed a Semi‐Markov state‐transition cohort disease simulation model that synthesised epidemiological, clinical and economic data to estimate the expected lifetime costs and quality‐adjusted life‐years (QALYs) associated with and without baseline testing for NS5A RAVs in EBR/GZR‐treated patients and with current treatments for GT1a patients. The model simulates the treatment regimens as well as the natural history of chronic HCV and predicts the lifetime incidence of end‐stage liver disease and death. The model is consistent with the current understanding of the biology of chronic HCV‐and liver disease and their treatment; is similar to other published cost‐effectiveness models of HCV disease,[12](#apt13882-bib-0012){ref-type="ref"}, [13](#apt13882-bib-0013){ref-type="ref"}, [14](#apt13882-bib-0014){ref-type="ref"}, [15](#apt13882-bib-0015){ref-type="ref"}, [16](#apt13882-bib-0016){ref-type="ref"} including our previously published and validated Markov cohort model[17](#apt13882-bib-0017){ref-type="ref"}, [18](#apt13882-bib-0018){ref-type="ref"}, [19](#apt13882-bib-0019){ref-type="ref"}; and its development and analysis follow accepted best practices.[20](#apt13882-bib-0020){ref-type="ref"}

The state‐transition model consists of several health states (Figure [1](#apt13882-fig-0001){ref-type="fig"}). The severity of chronic HCV infection is described by the degree of fibrosis using the METAVIR scoring system: no fibrosis (F0), portal fibrosis without septa (F1), portal fibrosis with few septa (F2), numerous septa without fibrosis (F3), and compensated cirrhosis (F4).

![State‐transition diagram for chronic hepatitis C and liver disease model. The model consists of the following health states: no fibrosis (F0), portal fibrosis without septa (F1), portal fibrosis with few septa (F2), portal fibrosis with numerous septa without cirrhosis (F3), compensated cirrhosis (F4), two decompensated cirrhosis (DC) states -- first year and subsequent years (PDC), two hepatocellular carcinoma (HCC) states -- first year and subsequent years (PHCC), two liver transplant states -- first year (LT) and subsequent years (PLT), End‐stage liver disease death (ELDS Death), death from all other causes (not shown here), and two sustained virological response (SVR) status states stratified by fibrosis stage -- 'SVR, F0--F3' and 'SVR, F4'.](APT-45-455-g001){#apt13882-fig-0001}

A subject with a given fibrosis score may progress to more severe stages of liver disease or may remain in that health state. In the absence of successful treatment, regression to less severe health states is not permitted. However, after a successful treatment, a subject can achieve a sustained virological response. To account for the possibility of HCV reinfection among high‐risk patients, the model allows for transitions from sustained virological response states to fibrosis states following reinfection and failure to clear the virus during the acute infection state. Only one‐time reinfection was considered and future diagnosis and treatment was not accounted for.

Patients with compensated cirrhosis are at risk for developing decompensated cirrhosis and hepatocellular carcinoma. If a patient develops decompensated cirrhosis and/or hepatocellular carcinoma then the patient may receive a liver transplant. Decompensated cirrhosis, hepatocellular carcinoma and liver transplant patients are subjected to excess mortality compared with the general population. To account for different mortality rates of decompensated cirrhosis, hepatocellular carcinoma and liver transplantation during the first year and subsequent years, each of these health states was divided into two states: first‐year state and subsequent‐years state. All other patients face the same mortality risk as the general population.

The model simulates the RAVs testing treatment strategies and 12‐week follow‐up and the natural history of HCV. The treatment and follow‐up period is not modelled separately from the natural history model. To simplify, the treatment phase of the model representing treatment and follow‐up period just determines whether a patient is either cured or not. The Markov part of the model is simulated using a cycle length of 1 year.

Testing and treatment comparators {#apt13882-sec-0009}
---------------------------------

EBR/GZR is indicated with or without ribavirin for treatment of chronic HCV genotypes 1 or 4 infection in adults. Testing for presence of NS5A RAVs polymorphisms at amino acid positions 28, 30, 31 or 93 prior to initiation of therapy is recommended for GT1a patients. In the clinical trials of EBR/GZR, the analyses were conducted using population nucleotide sequencing. Based on the test results, treatment‐naïve or PegIFN/RBV‐experienced GT1a patients without baseline NS5A polymorphisms are treated with EBR/GZR for 12 weeks whereas those with baseline NS5A polymorphisms are treated with EBR/GZR and RBV for 16 weeks.[3](#apt13882-bib-0003){ref-type="ref"}, [10](#apt13882-bib-0010){ref-type="ref"}

We consider four regimens: (i) EBR/GZR without any RAVs‐based testing (EBR/GZR+NoTesting), (ii) EBR/GZR with RAVs‐based testing (EBR/GZR+Testing), LDV/SOF, and ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) with or without ribavirin (Table [1](#apt13882-tbl-0001){ref-type="table"}). LDV/SOF regimens for treating naïve noncirrhotic patients with low viral load also included treatment for 8 weeks only. Per products' label, RAVs testing was not included in any of the LDV/SOF or 3D± RBV regimens.

###### 

Regimens and durations for treatment of HCV genotype 1a in patients with or without cirrhosis

  Patient Population: Regimen                                                                                                 Duration (weeks)   SVR (*n/N*)       Range          Probability distribution   Reference
  --------------------------------------------------------------------------------------------------------------------------- ------------------ ----------------- -------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------
  Treatment‐naïve or PegIFN/RBV‐experienced with and without cirrhosis, RAVs testing[a](#apt13882-note-0002){ref-type="fn"}                                                                                  
  Without baseline NS5A polymorphism[b](#apt13882-note-0003){ref-type="fn"}: EBR/GZR                                          12                 0.980 (441/450)   0.962--0.991   Beta (440.02, 8.98)        [3](#apt13882-bib-0003){ref-type="ref"}
  With baseline NS5A polymorphism: EBR/GZR+RBV                                                                                16                 1.000 (6/6)       0.541--1.000   Uniform (0, 1)^1/6^        [3](#apt13882-bib-0003){ref-type="ref"}
  Treatment‐naïve or PegIFN/RBV‐experienced with and without cirrhosis, no testing[a](#apt13882-note-0002){ref-type="fn"}                                                                                    
  Without baseline NS5A polymorphism: EBR/GZR                                                                                 12                 0.980 (441/450)   0.962--0.991   Beta (440.02, 8.98)        [3](#apt13882-bib-0003){ref-type="ref"}
  With baseline NS5A polymorphism: EBR/GZR                                                                                    12                 0.70 (39/56)      0.559--0.812   Beta (38.30, 16.70)        [3](#apt13882-bib-0003){ref-type="ref"}
  Treatment‐naïve without cirrhosis, no testing                                                                                                                                                              
  Without baseline NS5A polymorphism: LDV/SOF                                                                                 8                  0.965 (138/143)   0.92--0.989    Beta (137.03,4.97)         [22](#apt13882-bib-0022){ref-type="ref"}
  Without baseline NS5A polymorphism: LDV/SOF                                                                                 12                 0.983 (347/353)   0.963--0.994   Beta (346.02, 5.98)        [22](#apt13882-bib-0022){ref-type="ref"}, [23](#apt13882-bib-0023){ref-type="ref"}
  Without baseline NS5A polymorphism: 3D+ RBV                                                                                 12                 0.957 (402/420)   0.933--0.974   Beta (401.04, 17.96)       [26](#apt13882-bib-0026){ref-type="ref"}
  With baseline NS5A polymorphism: LDV/SOF                                                                                    8                  0.938 (30/32)     0.92--0.989    Beta (137.03, 4.97)        [22](#apt13882-bib-0022){ref-type="ref"}
  With baseline NS5A polymorphism: LDV/SOF                                                                                    12                 0.989 (187/189)   0.963--0.994   Beta (346.02, 5.98)        [22](#apt13882-bib-0022){ref-type="ref"}, [23](#apt13882-bib-0023){ref-type="ref"}
  With baseline NS5A polymorphism: 3D+ RBV                                                                                    12                 0.957 (402/420)   0.933--0.974   Beta (401.04, 17.96)       [26](#apt13882-bib-0026){ref-type="ref"}
  Treatment‐naïve with cirrhosis, no testing                                                                                                                                                                 
  Without baseline NS5A polymorphism: LDV/SOF                                                                                 12                 0.978 (45/46)     0.885--0.999   Beta (44.02, 0.98)         [24](#apt13882-bib-0024){ref-type="ref"}, [25](#apt13882-bib-0025){ref-type="ref"}
  Without baseline NS5A polymorphism: 3D+ RBV                                                                                 24                 0.946 (53/56)     0.851--0.989   Beta (52.05, 2.95)         [26](#apt13882-bib-0026){ref-type="ref"}
  With baseline NS5A polymorphism: LDV/SOF                                                                                    12                 0.978 (45/46)     0.885--0.999   Beta (44.02, 0.98)         [24](#apt13882-bib-0024){ref-type="ref"}, [25](#apt13882-bib-0025){ref-type="ref"}
  With baseline NS5A polymorphism: 3D+ RBV                                                                                    24                 0.946 (53/56)     0.851--0.989   Beta (52.05, 2.95)         [26](#apt13882-bib-0026){ref-type="ref"}
  PegIFN/RBV‐treatment‐experienced without cirrhosis, no testing                                                                                                                                             
  Without baseline NS5A polymorphism: LDV/SOF                                                                                 12                 0.97 (353/161)    0.931--0.99    Beta (160.03, 4.97)        [21](#apt13882-bib-0021){ref-type="ref"}, [24](#apt13882-bib-0024){ref-type="ref"}, [25](#apt13882-bib-0025){ref-type="ref"}
  Without baseline NS5A polymorphism: 3D+ RBV                                                                                 12                 0.96 (420/166)    0.918--0.984   Beta (165.04, 6.96)        [26](#apt13882-bib-0026){ref-type="ref"}
  With baseline NS5A polymorphism: LDV/SOF                                                                                    12                 0.97 (353/161)    0.931--0.99    Beta (160.03, 4.97)        [21](#apt13882-bib-0021){ref-type="ref"}, [24](#apt13882-bib-0024){ref-type="ref"}, [25](#apt13882-bib-0025){ref-type="ref"}
  With baseline NS5A polymorphism: 3D+ RBV                                                                                    12                 0.96 (420/166)    0.918--0.984   Beta (165.04, 6.96)        [26](#apt13882-bib-0026){ref-type="ref"}
  PegIFN/RBV‐treatment‐experienced with cirrhosis, no testing                                                                                                                                                
  Without baseline NS5A polymorphism: LDV/SOF+RBV                                                                             12                 0.961 (53/74)     0.89--0.992    Beta (73.04, 2.96)         [24](#apt13882-bib-0024){ref-type="ref"} ^,^ [38](#apt13882-bib-0038){ref-type="ref"}
  Without baseline NS5A polymorphism: LDV/SOF                                                                                 24                 0.98 (46/48)      0.891--0.999   Beta (47.02, 0.98)         [24](#apt13882-bib-0024){ref-type="ref"}
  Without baseline NS5A polymorphism: 3D+ RBV                                                                                 24                 0.954 (56/62)     0.871--0.99    Beta (61.05, 2.95)         [26](#apt13882-bib-0026){ref-type="ref"}
  With baseline NS5A polymorphism: LDV/SOF+RBV                                                                                12                 0.961 (53/74)     0.89--0.992    Beta (73.04, 2.96)         [24](#apt13882-bib-0024){ref-type="ref"}, [38](#apt13882-bib-0038){ref-type="ref"}
  With baseline NS5A polymorphism: LDV/SOF                                                                                    24                 0.98 (46/48)      0.891--0.999   Beta (47.02, 0.98)         [24](#apt13882-bib-0024){ref-type="ref"}, [38](#apt13882-bib-0038){ref-type="ref"}
  With baseline NS5A polymorphism: 3D+ RBV                                                                                    24                 0.954 (56/62)     0.871--0.99    Beta (61.05, 2.95)         [26](#apt13882-bib-0026){ref-type="ref"}

\*Patients who have failed treatment with peginterferon alfa (PegIFN) + ribavirin (RBV). Because the presence HCV NS5A amino acid polymorphisms was associated with reduced efficacy of EBR/GZR for 12 weeks regardless of prior treatment history or status, the SVR data were pooled across cirrhosis and prior treatment history status. EBR/GZR, elbasvir/grazoprevir; LDV/SOF, ledipasvir/sofosbuvir; 3D, ombitasvir/paritaprevir/ritonavir and dasabuvir; RBV, ribavirin.

†NS5A resistance‐associated polymorphisms at amino acid positions 28, 30, 31 or 93.
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Patient characteristics {#apt13882-sec-0010}
-----------------------

The target population is patients infected with chronic hepatitis C virus genotype 1a with or without prior treatment experience. The baseline patient characteristics for the analyses are based on published studies. Patient characteristics impact the efficacy of the treatment regimens, the rate of disease progression in patients who failed treatment, and annual mortality rate.

Treatment inputs {#apt13882-sec-0011}
----------------

Information concerning the treatment regimens was derived from the clinical trials and the published literature. This includes the treatment efficacy, discontinuation rates and side effects associated with antiviral therapy.

The safety and efficacy of EBR/GZR were evaluated in 8 clinical trials in approximately 1800 subjects with genotype (GT) 1, 3, 4 or 6 chronic hepatitis C infection with compensated (with and without cirrhosis) liver disease. The efficacy of the other regimens was obtained from clinical trials of LDV/SOF and 3D± RBV.[21](#apt13882-bib-0021){ref-type="ref"}, [22](#apt13882-bib-0022){ref-type="ref"}, [23](#apt13882-bib-0023){ref-type="ref"}, [24](#apt13882-bib-0024){ref-type="ref"}, [25](#apt13882-bib-0025){ref-type="ref"}, [26](#apt13882-bib-0026){ref-type="ref"}

The discontinuation rates and safety metrics associated with using EBR/GZR were derived from indirect unadjusted comparisons rather than a network meta‐analysis. Estimates of discontinuation rates and the probabilities of depression, anaemia and rash occurring during the use of any of the comparators were obtained from the Canadian Agency for Drugs and Technologies in Health Therapeutic Review.[27](#apt13882-bib-0027){ref-type="ref"}

Clinical inputs {#apt13882-sec-0012}
---------------

Estimates of fibrosis progression rates were based on a published meta‐analysis.[28](#apt13882-bib-0028){ref-type="ref"} Other clinical inputs are shown Table [2](#apt13882-tbl-0002){ref-type="table"}.

###### 

Clinical and other inputs used in the analysis

                                                Base‐case                                                                                                                            Range             Probability distribution   Reference
  --------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ----------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Annual transition probabilities                                                                                                                                                                                                 
  Fibrosis progression                          [28](#apt13882-bib-0028){ref-type="ref"}                                                                                                                                          
  F0 to F1                                      0.117                                                                                                                                0.104--0.130      Beta (274.6, 2072.8)       
  F1 to F2                                      0.085                                                                                                                                0.075--0.096      Beta (230.3, 2478.8)       
  F2 to F3                                      0.120                                                                                                                                0.109--0.133      Beta (337.9, 2478.2)       
  F3 to F4                                      0.116                                                                                                                                0.104--0.129      Beta (292.3, 2227.8)       
  Cirrhosis regression                                                                                                                                                                                                            
  SVR, F4 to SVR, F3                            0.086                                                                                                                                0.047--0.142      Beta (11.67, 123.39)       [39](#apt13882-bib-0039){ref-type="ref"}
  Cirrhosis progression                                                                                                                                                                                                           
  F4 to DC                                      0.029                                                                                                                                0.010--0.039      Beta (14.89, 498.62)       [40](#apt13882-bib-0040){ref-type="ref"}, [41](#apt13882-bib-0041){ref-type="ref"}, [42](#apt13882-bib-0042){ref-type="ref"}, [43](#apt13882-bib-0043){ref-type="ref"}, [44](#apt13882-bib-0044){ref-type="ref"}, [45](#apt13882-bib-0045){ref-type="ref"}
  F4 to HCC                                     0.028                                                                                                                                0.010--0.079      Beta (2.43, 84.41)         [39](#apt13882-bib-0039){ref-type="ref"} ^,^ [46](#apt13882-bib-0046){ref-type="ref"}, [47](#apt13882-bib-0047){ref-type="ref"}, [48](#apt13882-bib-0048){ref-type="ref"}, [49](#apt13882-bib-0049){ref-type="ref"}
  SVR, F4 to DC                                 0.008                                                                                                                                0.002--0.036      Beta (0.84, 103.66)        [45](#apt13882-bib-0045){ref-type="ref"} ^,^ [50](#apt13882-bib-0050){ref-type="ref"}
  SVR, F4 to HCC                                0.005                                                                                                                                0.002--0.013      Beta (0.50, 251.98)        [45](#apt13882-bib-0045){ref-type="ref"}, [50](#apt13882-bib-0050){ref-type="ref"}
  Reinfection, high‐risk patients                                                                                                                                                                                                 
  Annual reinfection rate                       0.024                                                                                                                                0.009--0.061      Beta (3.19, 129.92)        [51](#apt13882-bib-0051){ref-type="ref"} ^,^ [52](#apt13882-bib-0052){ref-type="ref"}
  Probability of chronicity                     0.75                                                                                                                                 0.364--0.793      Beta (11.91, 8.24)         [53](#apt13882-bib-0053){ref-type="ref"}
  Liver disease progression                                                                                                                                                                                                       
  DC to HCC                                     0.068                                                                                                                                0.030--0.083      Beta (23.51, 322.19)       [54](#apt13882-bib-0054){ref-type="ref"}
  Probability of receiving a liver transplant                                                                                                                                                                                     
  DC                                            0.023                                                                                                                                0.010--0.062      Beta (1.42, 87.06)         [55](#apt13882-bib-0055){ref-type="ref"} ^,^ [56](#apt13882-bib-0056){ref-type="ref"}
  HCC                                           0.040                                                                                                                                0.000--0.140      Beta (0.04, 5.18)          [57](#apt13882-bib-0057){ref-type="ref"}
  Mortality rates                                                                                                                                                                                                                 
  Age/sex‐specific all‐cause                                                                                                                                                                                                      [58](#apt13882-bib-0058){ref-type="ref"}
  DC (first year) mortality                     0.140                                                                                                                                0.065--0.190      Beta (16.44, 100.97)       [54](#apt13882-bib-0054){ref-type="ref"}
  DC (subsequent years) mortality               0.103                                                                                                                                0.065--0.190      Beta (9.26, 80.61)         [54](#apt13882-bib-0054){ref-type="ref"}
  HCC‐related mortality                         0.427                                                                                                                                0.330--0.860      Beta (5.29, 7.10)          [40](#apt13882-bib-0040){ref-type="ref"}
  LT (first year) mortality                     0.166                                                                                                                                0.060--0.420      Beta (2.56, 12.86)         [59](#apt13882-bib-0059){ref-type="ref"}
  LT (subsequent years) mortality               0.044                                                                                                                                0.060--0.420      Beta (0.18, 3.81)          [59](#apt13882-bib-0059){ref-type="ref"}
  Adverse events per regimen                                                                                                                                                                                                      
  Probability of depression                                                                                                                                                                                                       
  Elbasvir/grazoprevir                          0.019 (6/316)                                                                                                                        0.007--0.041      Beta (5.98, 309.02)        [3](#apt13882-bib-0003){ref-type="ref"}
  Elbasvir/grazoprevir with Ribavirin           0.038 (4/106)                                                                                                                        0.01--0.094       Beta (3.96, 101.04)        [3](#apt13882-bib-0003){ref-type="ref"}
  Ledipasvir/sofosbuvir                         0.003                                                                                                                                0--0.017          Beta (0.38, 145.46)        [27](#apt13882-bib-0027){ref-type="ref"}
  Ledipasvir/sofosbuvir with Ribavirin          0.084                                                                                                                                0.022--0.28       Beta (1.42, 15.41)         [27](#apt13882-bib-0027){ref-type="ref"}
  3D + RBV                                      0.058                                                                                                                                0.009--0.258      Beta (0.72, 11.72)         [27](#apt13882-bib-0027){ref-type="ref"}
  Probability of anaemia                                                                                                                                                                                                          
  Elbasvir/grazoprevir                          0.006 (2/316)                                                                                                                        0.001--0.023      Beta (1.99, 313.01)        [3](#apt13882-bib-0003){ref-type="ref"}
  Elbasvir/grazoprevir with ribavirin           0.16 (17/106)                                                                                                                        0.096--0.244      Beta (16.84, 88.16)        [3](#apt13882-bib-0003){ref-type="ref"}
  Ledipasvir/sofosbuvir                         0.012                                                                                                                                0.004--0.033      Beta (2.64, 219.04)        [27](#apt13882-bib-0027){ref-type="ref"}
  Ledipasvir/sofosbuvir with Ribavirin          0.060                                                                                                                                0.024--0.129      Beta (4.56, 71.82)         [27](#apt13882-bib-0027){ref-type="ref"}
  3D + RBV                                      0.082                                                                                                                                0.028--0.206      Beta (2.92, 32.79)         [27](#apt13882-bib-0027){ref-type="ref"}
  Probability of rash                                                                                                                                                                                                             
  Elbasvir/grazoprevir                          0.019 (6/316)                                                                                                                        0.007--0.041      Beta (5.98, 309.02)        [3](#apt13882-bib-0003){ref-type="ref"}
  Elbasvir/grazoprevir with Ribavirin           0.075 (8/106)                                                                                                                        0.033--0.143      Beta (7.92, 97.08)         [3](#apt13882-bib-0003){ref-type="ref"}
  Ledipasvir/sofosbuvir                         0.048                                                                                                                                0.021--0.105      Beta (4.7, 93.2)           [27](#apt13882-bib-0027){ref-type="ref"}
  Ledipasvir/sofosbuvir with Ribavirin          0.085                                                                                                                                0.035--0.21       Beta (3.26, 34.97)         [27](#apt13882-bib-0027){ref-type="ref"}
  3D + RBV                                      0.132                                                                                                                                0.055--0.284      Beta (4.29, 28.24)         [27](#apt13882-bib-0027){ref-type="ref"}
  Anti‐viral therapy weekly cost                                                                                                                                                                                                  
  Elbasvir/grazoprevir                          4550                                                                                                                                                                              [29](#apt13882-bib-0029){ref-type="ref"}
  Elbasvir/grazoprevir with ribavirin           4921                                                                                                                                                                              
  Ledipasvir/sofosbuvir                         7875                                                                                                                                                                              
  Ledipasvir/sofosbuvir with Ribavirin          8246                                                                                                                                                                              
  3D + RBV                                      5500                                                                                                                                                                              
  Adverse event cost during treatment           [31](#apt13882-bib-0031){ref-type="ref"}                                                                                                                                          
  Cost of treating depression per episode       2837                                                                                                                                 2128--3546        Gamma (61.47, 46.16)       
  Cost of treating anaemia per episode          4209                                                                                                                                 3157--5261        Gamma (61.47, 68.48)       
  Cost of treating rash per episode             475                                                                                                                                  356--594          Gamma (61.47, 7.73)        
  One‐time baseline RAVs testing cost           563                                                                                                                                  422--704                                     [30](#apt13882-bib-0030){ref-type="ref"}
  Annual health state costs                     [17](#apt13882-bib-0017){ref-type="ref"} ^,^ [60](#apt13882-bib-0060){ref-type="ref"} ^,^ [61](#apt13882-bib-0061){ref-type="ref"}                                                
  F0--F1                                        739                                                                                                                                  555--924          Gamma (61.47, 12.03)       
  F2                                            749                                                                                                                                  561--936          Gamma (61.47, 12.03)       
  F3                                            1520                                                                                                                                 1140--1900        Gamma (61.47, 12.18)       
  Compensated cirrhosis                         1773                                                                                                                                 1329--2216        Gamma (61.47, 24.72)       
  DC                                            19 695                                                                                                                               14 771--24 619    Gamma (61.47, 28.84)       
  Post DC                                       19 695                                                                                                                               14 771--24 619    Gamma (61.47, 320.43)      
  HCC                                           36 218                                                                                                                               27 163--45 272    Gamma (61.47, 320.43)      
  Post HCC                                      36 218                                                                                                                               27 163--45 272    Gamma (61.47, 589.24)      
  Liver transplant (first year)                 104 730                                                                                                                              78 547--130 912   Gamma (61.47, 589.24)      
  Liver transplant (subsequent years)           27 484                                                                                                                               20 613--34 355    Gamma (61.47, 1703.88)     
  Annual discount rate of future cost           3%                                                                                                                                   0--5%                                        
  Health‐related quality of life inputs                                                                                                                                                                                           
  Drug therapy‐related multiplier (RBV)         0.85                                                                                                                                 0.81--0.89        Beta (1537, 0.001)         [32](#apt13882-bib-0032){ref-type="ref"}
  Drug therapy‐related multiplier (no RBV)      1.00                                                                                                                                 0.95--1.05        Gamma (1703, 0.001)        [62](#apt13882-bib-0062){ref-type="ref"}
  F0--F3                                        0.73/0.86                                                                                                                            0.81--0.89        Beta (231.43, 41.21)       [63](#apt13882-bib-0063){ref-type="ref"}
  Compensated cirrhosis                         0.69/0.86                                                                                                                            0.76--0.84        Beta (302.95, 74.64)       [63](#apt13882-bib-0063){ref-type="ref"}
  DC, post DC                                   0.65/0.86                                                                                                                            0.72--0.79        Beta (374.47, 120.98)      [63](#apt13882-bib-0063){ref-type="ref"}
  HCC, post HCC\*                               0.65/0.86                                                                                                                            0.72--0.79        Beta (374.47, 120.98)      [63](#apt13882-bib-0063){ref-type="ref"}
  First‐year, post liver transplant             0.75/0.86                                                                                                                            0.83--0.92        Beta (195.67, 28.7)        [63](#apt13882-bib-0063){ref-type="ref"}
  Post SVR, F0--F3                              0.75/0.86                                                                                                                            0.83--0.92        Beta (195.67, 28.7)        [63](#apt13882-bib-0063){ref-type="ref"}
  Post SVR, F4                                  0.76/0.86                                                                                                                            0.84--0.93        Beta (177.80, 23.39)       [63](#apt13882-bib-0063){ref-type="ref"}
  US population norms, men                      [64](#apt13882-bib-0064){ref-type="ref"}                                                                                                                                          
  20--29 years                                  0.928                                                                                                                                0.922--0.934      Beta (6616.65, 513.36)     
  30--39 years                                  0.918                                                                                                                                0.912--0.925      Beta (7374.1, 658.69)      
  40--49 years                                  0.887                                                                                                                                0.880--0.894      Beta (6970.14, 887.97)     
  50--59 years                                  0.861                                                                                                                                0.853--0.870      Beta (6185.19, 998.54)     
  60--69 years                                  0.84                                                                                                                                 0.827--0.852      Beta (2566.28, 488.82)     
  70--79 years                                  0.802                                                                                                                                0.788--0.816      Beta (2496.15, 616.26)     
  80--89 years                                  0.782                                                                                                                                0.757--0.807      Beta (819.41, 228.43)      
  US population norms, women                    [64](#apt13882-bib-0064){ref-type="ref"}                                                                                                                                          
  20--29 years                                  0.913                                                                                                                                0.905--0.920      Beta (4353.04, 414.8)      
  30--39 years                                  0.893                                                                                                                                0.886--0.900      Beta (6689.64, 801.56)     
  40--49 years                                  0.863                                                                                                                                0.855--0.871      Beta (6124.55, 972.26)     
  50--59 years                                  0.837                                                                                                                                0.829--0.846      Beta (6854.42, 1334.85)    
  60--69 years                                  0.811                                                                                                                                0.800--0.822      Beta (3946.67, 919.75)     
  70--79 years                                  0.771                                                                                                                                0.758--0.784      Beta (3094.35, 919.07)     
  80--89 years                                  0.724                                                                                                                                0.701--0.747      Beta (1050.61, 400.51)     

SVR, sustained virological response; F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis with few septa; F3, numerous septa without cirrhosis; F4, cirrhosis; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; 3D, ombitasvir/paritaprevir/ritonavir and dasabuvir; RBV, ribavirin.
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Cost inputs {#apt13882-sec-0013}
-----------

The weekly wholesale acquisition costs of anti‐viral therapies were obtained from the First DataBank.[29](#apt13882-bib-0029){ref-type="ref"} Costs of NS5A RAVs testing were based on the national median reimbursement rate for commercial insurance plans as listed in the National Fee Analyzer by Optum[30](#apt13882-bib-0030){ref-type="ref"} (Table [2](#apt13882-tbl-0002){ref-type="table"}). The cost of treating adverse events was obtained from a published study.[31](#apt13882-bib-0031){ref-type="ref"}

The health state costs associated with disease progression (e.g. diagnostic tests, visits, hospitalisation) were based on the published literature (Table [2](#apt13882-tbl-0002){ref-type="table"}).

Health‐related quality‐of‐life inputs {#apt13882-sec-0014}
-------------------------------------

Utility weights during the treatment phase and for each of the HCV health states and liver disease conditions were used to adjust quality of life of survivors (Table [2](#apt13882-tbl-0002){ref-type="table"}). On‐treatment, disutility was applied during the treatment period for regimens containing ribavirin. Disutility of treatment of 0.11 from a base utility of 0.77 for mild and 0.66 for moderate HCV was estimated by comparing patients treated with PegINF or RBV vs. no therapy using the EQ‐5D instrument, resulting in an average treatment multiplier of 0.85.[32](#apt13882-bib-0032){ref-type="ref"}

To avoid double counting the disutility of adverse events (as these are accounted for with the on‐treatment disutility) no quality of life multipliers for anaemia, depression or rash were applied for the patients experiencing theses adverse events.

Model validation {#apt13882-sec-0015}
----------------

The face validity of the model was checked during collaboration with clinicians, health economists and decision scientists, and by comparing its structure with that of previously published models.[12](#apt13882-bib-0012){ref-type="ref"}, [13](#apt13882-bib-0013){ref-type="ref"}, [14](#apt13882-bib-0014){ref-type="ref"}, [15](#apt13882-bib-0015){ref-type="ref"}, [16](#apt13882-bib-0016){ref-type="ref"} Several tests were built into the model for verification and to ensure internal validity. For example, the sum of the distribution of persons in each health state at the end of each cycle was verified to be equal to 1 both numerically using Excel and analytically by transferring the formula into Mathematica and using the built‐in algebraic functions within Mathematica to manipulate the resulting expressions. The model was also programmed in R and outcomes from the two programmes were compared. The results were the same (up to the rounding precision in the values). We cross‐validated the model by comparing its prediction of a 20‐year probability of compensated cirrhosis with that of previous models.[14](#apt13882-bib-0014){ref-type="ref"}, [33](#apt13882-bib-0033){ref-type="ref"} These models predicted the 20‐year probability of compensated cirrhosis among untreated 44‐years‐old patients with mild chronic HCV between 27% and 29%. Assuming that the respective distribution of mild HCV between F0 and F1 is 35% and 65%, the model projected the 20‐year probability of compensated cirrhosis at 29.7%.

Model analysis {#apt13882-sec-0016}
--------------

The model was run for each of the specified patient profiles. Depending on the type of analysis an overall weighted average of the results was generated based on the distribution of the patient characteristics assumed for a given analysis.

We applied within‐cycle correction to all cumulative outcomes using Simpson\'s 1/3rd rule and tested sensitivity of the results to the method of correction by applying the standard application of half‐cycle correction method.[34](#apt13882-bib-0034){ref-type="ref"} For the cost‐effectiveness analysis, we calculated costs and QALYs over the remaining duration of a patient\'s lifetime. Cost‐effectiveness of an EBR/GZR regimen relative to a comparator was evaluated using the incremental cost‐effectiveness ratio (ICER) obtained by dividing incremental total discounted costs by the incremental total discounted number of QALYs resulting from using EBR/GZR regimen instead of the comparator.

Base‐case analysis {#apt13882-sec-0017}
------------------

Aggregated results are presented separately by cirrhosis status and previous treatment history.

Subgroup analysis {#apt13882-sec-0018}
-----------------

The results are also provided separately by each fibrosis stage. The robustness of the results was also tested by changing the baseline demographic characteristics such as sex (i.e. men only and women only) and age distribution.

Deterministic sensitivity analysis {#apt13882-sec-0019}
----------------------------------

We conducted one‐way deterministic sensitivity analysis for several parameters showing the effect of varying these inputs on the ICER of EBR/GZR treatment strategies compared with no testing. We varied progression rates, efficacy, unit costs, utility weights, discount rates using the ranges defined in the inputs tables (Table [2](#apt13882-tbl-0002){ref-type="table"}).

Probabilistic sensitivity analysis {#apt13882-sec-0020}
----------------------------------

In order to quantify systematically the impact of overall uncertainty in the estimated values of transition probabilities, sustained virological response rates, costs and utility weights on the ICER of EBR/GZR treatment strategies compared with standard of care, we performed probabilistic sensitivity analysis. Using Monte Carlo simulations methods, we drew 10 000 random samples from pre‐defined distributions (Tables [1](#apt13882-tbl-0001){ref-type="table"} and [2](#apt13882-tbl-0002){ref-type="table"}).

The parameters of the Gamma and Beta distributions were estimated using the method of moments that relates each parameter to the mean and standard deviation. We used the base‐case values as estimates of the mean. Standard errors were estimated from confidence intervals or ranges (Appendix S1).

Results of the probabilistic sensitivity analysis were presented using cost‐effectiveness acceptability curves.[35](#apt13882-bib-0035){ref-type="ref"} This curve summarises uncertainty in the results of the cost‐effectiveness analysis by showing the probability a regimen is cost‐effective as a function of willingness‐to‐pay for a QALY gained.

To determine which strategy is cost‐effective at a threshold of willingness‐to‐pay of \$50 000/QALY in the one‐way sensitivity analysis and probabilistic sensitivity analysis, we calculated the net monetary benefit = (incremental QALYs)\*(willingness‐to‐pay) − incremental costs.

Results {#apt13882-sec-0021}
=======

Base‐case results {#apt13882-sec-0022}
-----------------

The lifetime cost‐effectiveness analysis showed that noncirrhotic treatment‐naïve individuals with GT1a who followed an EBR/GZR RAVs testing‐based strategy accrued more QALYs than individuals without testing who received EBR/GZR, 3D+RBV, and 8 weeks of LDV/SOF (Table [3](#apt13882-tbl-0003){ref-type="table"}). The strategy that included testing also had lower total cost than 3D+RBV or 8 weeks of LDV/SOF. As a result, the RAVs testing‐based strategy dominated 3D+RBV or 8 weeks of LDV/SOF and had an ICER of \$25 471 compared with EBR/GZR without testing. Although 12 weeks of treatment with LDV/SOF yielded higher QALYs, it produced an ICER of more than \$4 million/QALY compared with the EBR/GZR RAVs testing ‐based strategy (Table [3](#apt13882-tbl-0003){ref-type="table"}).

###### 

Total discounted expected costs and QALYs, and the incremental cost‐effectiveness ratio associated with each treatment regimen

  Patient population and treatment regimen             Total discounted QALYs (years)   Total cost (\$)   ICER (\$/QALYs)
  ---------------------------------------------------- -------------------------------- ----------------- -----------------
  Treatment naïve patients without cirrhosis                                                              
  EBR/GZR + no testing12 weeks                         14.1596                          59 817            --
  3D± RBV 12 weeks                                     14.1791                          75 651            Dominated
  LDV/SOF 8 weeks                                      14.2402                          66 599            Dominated
  EBR/GZR± RBV + testing                               14.2458                          62 013            25 471
  LDV/SOF 12 weeks                                     14.2539                          96 722            4 303 701
  Treatment naïve patients with cirrhosis                                                                 
  3D± RBV 24 weeks                                     12.6906                          159 245           Dominated
  EBR/GZR + no testing 12 weeks                        12.7904                          73 370            --
  LDV/SOF 12 weeks                                     12.9556                          109 651           Dominated
  EBR/GZR± RBV + testing                               12.9707                          74 659            7154
  PegIFN/RBV‐treatment‐experienced without cirrhosis                                                      
  EBR/GZR + no testing 12 weeks                        14.1596                          59 817            --
  3D± RBV 12 weeks                                     14.1930                          75 838            Dominated
  LDV/SOF 12 weeks                                     14.2209                          97 198            Dominated
  EBR/GZR± RBV + testing                               14.2458                          62 013            25 471
  PegIFN/RBV‐treatment‐experienced with cirrhosis                                                         
  3D± RBV 24 weeks                                     12.7438                          158 795           Dominated
  EBR/GZR+no testing                                   12.7904                          73 370            --
  LDV/SOF+RBV 12 weeks                                 12.8602                          115 507           Dominated
  LDV/SOF 24 weeks                                     12.8765                          202 789           Dominated
  EBR/GZR± RBV + testing                               12.9707                          74 660            7153

EBR/GZR, elbasvir/grazoprevir; ICER, incremental cost‐effectiveness ratio; LDV/SOF, ledipasvir/sofosbuvir; 3D, ombitasvir/paritaprevir/ritonavir and dasabuvir; RBV, ribavirin; QALY, quality‐adjusted life year.

John Wiley & Sons, Ltd

Treatment with EBR/GZR guided by RAVs testing is the most effective regimen among treatment‐experienced patients without cirrhosis and cirrhotic patients regardless of prior treatment status. The ICER of this strategy compared with EBR/GZR without testing in treatment‐naive or treatment‐experienced patients with cirrhosis is \$7154/QALY. The ICER in treatment‐experienced patients without cirrhosis was \$25 471.

Results of subgroup analysis {#apt13882-sec-0023}
----------------------------

The results of the subgroup analysis suggest that the ICER of the strategy that included testing compared with EBR/GZR without testing decreased with the severity of fibrosis/cirrhosis (from \$57 800/QALY among F0 patients to \$7200/QALY among cirrhotic patients). Changing the baseline demographic characteristics from men only to women only had little impact on the results (Figure S1).

Results of sensitivity analyses {#apt13882-sec-0024}
-------------------------------

Variations of inputs in one‐way sensitivity analysis within the range suggested that the results are most sensitive to sustained virological response rates and cost of anti‐viral therapy. For example, decreasing the cost of LDV/SOF by 25% resulted in LDV/SOF8 being the only cost‐effective option. However, decreasing or increasing the costs of EBR/GZR by 25% did not alter the qualitative results of the base case. Overall, testing‐guided treatment of patients without cirrhosis with EBR/GZR was cost‐effective at a threshold of willingness‐to‐pay of \$50 000/QALY in 92 of 93 one‐way sensitivity analyses (Table S1).

The cost‐effectiveness acceptability curves showed that treatment of noncirrhotic treatment‐naïve patients with EBR/GZR based on RAVs testing results was cost‐effective in 48%, whereas treatment with EBR/GZR irrespective of RAVs status is cost‐effective in 40% in all 10 000 simulations at the threshold of \$50 000 per QALY (Figure [2](#apt13882-fig-0002){ref-type="fig"}). Among this patient population, LDV/SOF8 was cost‐effective in 12% whereas OMB/PAR/RIT/DAS± RBV or LDV/SOF12 was not cost‐effective in any of the simulations. Retreatment of noncirrhotic patients with EBR/GZR guided by RAVs testing was cost‐effective in 55% of the simulations (Figure [3](#apt13882-fig-0003){ref-type="fig"}).

![Cost‐effectiveness acceptability curve showing probability of optimal regimen for treatment‐naïve patients without cirrhosis among EBR/GZR with RAVs testing, EBR/GZR without testing, LDV/SOF, and 3D for a range of maximum willingness‐to‐pay for a quality‐adjusted life‐year (QALY) saved. EBR/GZR, elbasvir/grazoprevir; LDV/SOF, ledipasvir/sofosbuvir; 3D, ombitasvir/paritaprevir/ritonavir and dasabuvir; RBV, ribavirin.](APT-45-455-g002){#apt13882-fig-0002}

![Cost‐effectiveness acceptability curve showing probability of optimal regimen for treatment‐experienced patients without cirrhosis among EBR/GZR with RAVs testing, EBR/GZR without testing, LDV/SOF, and 3D for a range of maximum willingness‐to‐pay for a quality‐adjusted life‐year (QALY) saved. EBR/GZR, elbasvir/grazoprevir; LDV/SOF, ledipasvir/sofosbuvir; 3D, ombitasvir/paritaprevir/ritonavir and dasabuvir; RBV, ribavirin.](APT-45-455-g003){#apt13882-fig-0003}

Treatment with EBR/GZR based on RAVs testing results was cost‐effective in 63% and 85% of the simulations among cirrhotic treatment‐naïve and treatment‐experienced patients, respectively (Figures [4](#apt13882-fig-0004){ref-type="fig"} and [5](#apt13882-fig-0005){ref-type="fig"}).

![Cost‐effectiveness acceptability curve showing probability of optimal regimen for treatment‐naïve patients with cirrhosis among EBR/GZR with RAVs testing, EBR/GZR without testing, LDV/SOF, and 3D for a range of maximum willingness‐to‐pay for a quality‐adjusted life‐year (QALY) saved. EBR/GZR, elbasvir/grazoprevir; LDV/SOF, ledipasvir/sofosbuvir; 3D, ombitasvir/paritaprevir/ritonavir and dasabuvir; RBV, ribavirin.](APT-45-455-g004){#apt13882-fig-0004}

![Cost‐effectiveness acceptability curve showing probability of optimal regimen for treatment‐experienced patients with cirrhosis among EBR/GZR with RAVs testing, EBR/GZR without testing, LDV/SOF, and 3D for a range of maximum willingness‐to‐pay for a quality‐adjusted life‐year (QALY) saved. EBR/GZR, elbasvir/grazoprevir; LDV/SOF, ledipasvir/sofosbuvir; 3D, ombitasvir/paritaprevir/ritonavir and dasabuvir; RBV, ribavirin.](APT-45-455-g005){#apt13882-fig-0005}

Discussion {#apt13882-sec-0025}
==========

The presence of NS5A RAVs can attenuate the efficacy of new direct‐acting antivirals. Testing for RAVs prior to the selecting of the next HCV treatment regimen has the potential to improve efficacy, but adds to cost of therapy. Therefore, it is important to assess the cost‐effectiveness of baseline testing for NS5A RAVs in EBR/GZR‐treated GT1 patients.

This study showed that RAVs testing‐based strategy is superior to 3D+RBV or 8 weeks of LDV/SOF and is cost‐effective compared with EBR/GZR without testing. This conclusion is robust in several sensitivity analyses. To our knowledge this is the first study to assess the utility of RAVs testing for guiding HCV treatment with new direct‐acting antivirals.

Although this study demonstrated the utility of baseline testing for NS5A RAVs in EBR/GZR‐treated patients, RAVs testing has some potential challenges. Currently, the availability of testing for the presence of baseline RAVs varies from place to place, providers are not familiar with the test, and there is no standardised assay for the determination of resistance.

This study had some limitations. First, it excluded the risk of hepatocellular carcinoma even among patients with advanced fibrosis F3. This has the potential of biasing the results against treatment. Second, to simplify the analysis, we did not take into account the fact that patients failing to achieve a sustained virological response may be also retreated with a different regimen. This is unlikely to be a major limitation because only a small percentage of patients fail to achieve a sustained virological response when treated for the first time with currently available direct‐acting antivirals. Third, efficacy inputs were based on data from individual clinical trials with no head‐to‐head comparative data. Some of these estimates were obtained from *post hoc* analysis which has its own methodological limitations. In addition, conducting *post hoc* analysis created a practical challenge. Among the patients receiving EBR/GZR+RBV for 16 weeks, only a small group of patients harboured NS5A RAVs that reduced the efficacy of the EBR/GZR regimen. As a result, the sample size in the EBR/GZR +RBV arm was relatively small (i.e. *n* = 6). This manifested itself in the decision uncertainty regarding RAVs testing, where it was cost‐effective in only 48--55% of the simulations of noncirrhotic patients. Fourth, we assumed the efficacy of LDV/SOF and 3D is not affected by RAVs status. There are limited recent data that contradict this assumption.[6](#apt13882-bib-0006){ref-type="ref"}, [36](#apt13882-bib-0036){ref-type="ref"} Finally, the study did not consider all regimens currently available to treat GT1a patients, including simeprevir plus sofosbuvir with or without weight‐based ribavirin and daclatasvir plus sofosbuvir with or without weight‐based ribavirin. This exclusion also covered the very recently launched regimen sofosbuvir/velpatasvir as it was not approved at the time of the analysis.[10](#apt13882-bib-0010){ref-type="ref"}

Despite these limitations our conclusion regarding the cost‐effectiveness of EBR/GZR‐based regimens in chronic GT1a patients is robust to variation in many model inputs.

Several other modelling studies of cost‐effectiveness of treating chronic hepatitis C patients in the USA have shown that treatment with all‐oral direct‐acting antivirals is a good use of limited healthcare resources.[37](#apt13882-bib-0037){ref-type="ref"} Our results are broadly consistent with those of studies of general HCV patients.

In conclusion, this analysis has demonstrated that RAVs testing before treatment with EBR/GZR is likely to be a cost‐effective alternative to the use of EBR/GZR without testing, LDV/SOF, or 3D among GT1a treatment‐naïve or treatment experienced patients.
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**Table S1.** Deterministic one‐way sensitivity analysis: net monetary benefit by strategy and input values.

**Figure S1.** Incremental cost‐effectiveness ratio of EBR/GZR with testing vs. no testing by baseline fibrosis/cirrhosis status.
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